Fig S2 from Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations
Year: 2023
Type: other
Abstract: Fig S2. Nonsynonymous (left panel) and overall (right panel) tumor mutation burden (TMB) for subjects that achieved clinical benefit and those who had no clinical benefit (NCB). TMB for each patient is SNVs/indels per megabase of targeted capture genomic region. The horizontal bars indicate median values. Note that y axis is log scale. Abbreviations: UTUC - upper tract urothelial carcinoma.
Authors: Elio Adib, Katarzyna Klonowska, Krinio Giannikou, Khanh T. Do, Solida Pruitt-Thompson, Ketki Bhushan, Matthew I. Milstein, Jennifer Hedglin, Katherine E. Kargus, Lynette M. Sholl, Junko Tsuji, David M. Hyman, Anne Sisk, Geoffrey I. Shapiro, Hebert A. Vargas, James J. Harding, Martin H. Voss, Gopa Iyer, David J. Kwiatkowski
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361939137